CASRN: 149394-66-1
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of cidofovir during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during cidofovir therapy. An alternate drug is preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Monkeypox) Tecovirimat
Substance Identification
Substance Name
Cidofovir
CAS Registry Number
149394-66-1
Drug Class
Breast Feeding
Lactation
Milk, Human
Anti-Infective Agents
Antiviral Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
Publication Details
Publication History
Last Revision: August 15, 2022.
Copyright
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Publisher
National Institute of Child Health and Human Development, Bethesda (MD)
NLM Citation
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Cidofovir. [Updated 2022 Aug 15].